A comparative study of two PODXL antibodies in 840 colorectal cancer patients

BMC Cancer

Tuomas Kaprio³  Jaana Hagström⁴  Christian Fermér²  Harri Mustonen¹  Camilla Böckelman⁶  Olle Nilsson⁵  Caj Haglund³ 

[1] Department of Surgery, Helsinki University Central Hospital, P.O. Box 440, 00029 HUS Helsinki, Finland

[2] Fujirebio Diagnostics AB, Elof Lindälvs gata 13, SE-414 58 Göteborg, Sweden

[3] Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland

[4] Department of Pathology, Haartman Institute, University of Helsinki and HUSLAB, Helsinki FIN-00014 HY, Finland

[5] Onson Consulting, Södra vägen 2, SE-412 54 Göteborg, Sweden

[6] Department of Surgery, Vaasa Central Hospital, Sandviksgatan 2-4, 65100 Vaasa VASA, Finland

关键词: Prognosis;    Podocalyxin;    Colorectal cancer;   

Others  :  856925
DOI  :  10.1186/1471-2407-14-494

 received in 2014-05-23, accepted in 2014-07-02,  发布年份 2014

【 摘 要 】

Background

Podocalyxin (PODXL) is a transmembrane sialomucin, whose aberrant expression and/or allelic variation associates with poor prognosis and unfavourable clinicopathological characteristics in different cancers. Membranous expression of PODXL has been suggested to be an independent marker of poor prognosis in colorectal cancer (CRC), and previously by an in-house monoclonal antibody, we showed that also cytoplasmic overexpression of PODXL predicts poor prognosis. The aim of this study was to compare two PODXL antibodies with different epitopes case-by-case in CRC patients.

Methods

Of 840 consecutively operated CRC patients from Helsinki University Central Hospital, PODXL expression by polyclonal HPA 2110 antibody was evaluated from 780. Associations of PODXL expression with clinicopathological parameters and the impact of PODXL expression on survival were assessed. Kappa-value was used to assess the comparability of the two antibodies.

Results

Membranous PODXL expression associated with unfavourable clinicopathological parameters and with higher risk for disease-specific death from CRC within 5 years (unadjusted hazard ratio (HR) = 1.90; 95% confidence interval (CI) (1.32-2.75); adjusted HR = 1.64; 95% CI (1.11-2.43)). The comparability of expressions by the two antibodies was low (kappa =0.219, standard error 0.060, p < 0.0001). Combination of two antibodies identified a group of patients with even worse prognosis (unadjusted HR = 6.00; 95% CI (3.27-13.0); adjusted HR = 2.14; 95% CI (1.12-4.07)).

Conclusion

Membranous expression by the polyclonal PODXL antibody and cytoplasmic overexpression by the monocolonal PODXL antibody are both independent markers of poor prognosis, but they recognise different groups of patients, both of which have poor prognosis. The combined use of the antibodies reveals a group with an even worse prognosis. The biological reasons for the difference between antibodies warrant further studies.

【 授权许可】

   
2014 Kaprio et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
• [2]O’Connor ESE, Greenblatt DYD, LoConte NKN, Gangnon RER, Liou J-IJ, Heise CPC, Smith MAM: Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011, 29:3381-3388.
• [3]Kerjaschki D, Noronha-Blob L, Sacktor B, Farquhar MG: Microdomains of distinctive glycoprotein composition in the kidney proximal tubule brush border. The Journal of cell biology 1984, 98(4):1505-1513.
• [4]Horvat RR, Hovorka AA, Dekan GG, Poczewski HH, Kerjaschki DD: Endothelial cell membranes contain podocalyxin–the major sialoprotein of visceral glomerular epithelial cells. J Cell Biol 1986, 102:484-491.
• [5]Somasiri A, Nielsen JS, Makretsov N, McCoy ML, Prentice L, Gilks CB, Chia SK, Gelmon KA, Kershaw DB, Huntsman DG, McNagny KM, Roskelley CD: Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res 2004, 64:5068-5073.
• [6]Doyonnas RR, Nielsen JSJ, Chelliah SS, Drew EE, Hara TT, Miyajima AA, McNagny KMK: Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells. Blood 2005, 105:4170-4178.
• [7]Kershaw DBD, Beck SGS, Wharram BLB, Wiggins JEJ, Goyal MM, Thomas PEP, Wiggins RCR: Molecular cloning and characterization of human podocalyxin-like protein. Orthologous relationship to rabbit PCLP1 and rat podocalyxin. J Biol Chem 1997, 272:15708-15714.
• [8]Richards MM, Tan S-PS, Tan J-HJ, Chan W-KW, Bongso AA: The transcriptome profile of human embryonic stem cells as defined by SAGE. Stem Cells 2003, 22:51-64.
• [9]Nielsen JS, McNagny KM: The role of podocalyxin in health and disease. J Am Soc Nephrol 2009, 20:1669-1676.
• [10]Dallas MR, Chen S-H, Streppel MM, Sharma S, Maitra A, Konstantopoulos K: Sialofucosylated podocalyxin is a functional E- and L-selectin ligand expressed by metastatic pancreatic cancer cells. Am J Physiol Cell Physiol 2012, 303:C616-C624.
• [11]Konstantopoulos K, Thomas SN: Cancer cells in transit: the vascular interactions of tumor cells. Annu Rev Biomed Eng 2009, 11:177-202.
• [12]Thomas SN, Schnaar RL, Konstantopoulos K: Podocalyxin-like protein is an E-/L-selectin ligand on colon carcinoma cells: comparative biochemical properties of selectin ligands in host and tumor cells. Am J Physiol Cell Physiol 2009, 296:C505-C513.
• [13]Meng X, Ezzati P, Wilkins JA: Requirement of podocalyxin in TGF-beta induced epithelial mesenchymal transition. PLoS One 2011, 6:e18715.
• [14]Casey GG, Neville PJP, Liu XX, Plummer SJS, Cicek MSM, Krumroy LML, Curran APA, McGreevy MRM, Catalona WJW, Klein EAE, Witte JSJ: Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. Hum Mol Genet 2006, 15:735-741.
• [15]Nielsen JS, Graves ML, Chelliah S, Vogl AW, Roskelley CD, McNagny KM: The CD34-related molecule podocalyxin is a potent inducer of microvillus formation. PLoS One 2007, 2:e237.
• [16]Hsu Y-HY, Lin W-LW, Hou Y-TY PY-SY, Shun C-TC, Chen C-LC WY-YY, Chen J-YJ, Chen T-HT, Jou T-ST: Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7. Am J Pathol 2010, 176:12-12.
• [17]Larsson A, Johansson ME, Wangefjord S, Gaber A, Nodin B, Kucharzewska P, Welinder C, Belting M, Eberhard J, Johnsson A, Uhlén M, Jirström K: Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer 2011, 105:666-672.
• [18]Boman K, Larsson AH, Segersten U, Kuteeva E, Johannesson H, Nodin B, Eberhard J, Uhlén M, Malmström P-U, Jirström K: Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer. Br J Cancer 2013, 108(11):2321-2328.
• [19]Schopperle WM, Kershaw DB, DeWolf WC: Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem Biophys Res Commun 2003, 300:285-290.
• [20]Larsson A, Fridberg M, Gaber A, Nodin B, Levéen P, Jönsson G, Uhlén M, Birgisson H, Jirström K: Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer. BMC Cancer 2012, 12:282-282.
• [21]Kaprio T, Fermér C, Hagström J, Mustonen H, Böckelman C, Nilsson O, Haglund C: Podocalyxin is a marker of poor prognosis in colorectal cancer. BMC Cancer 2014, 14:493.
• [22]Kononen J, Bubendorf L, Kallionimeni A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallionimeni O-P: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847.
• [23]Uhlens M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, Berglund L, Bergstrom K, Brumer H, Cerjan D, Ekstrom M, Elobeid A, Eriksson C, Fagerberg L, Falk R, Fall J, Forsberg M, Bjorklund MG, Gumbel K, Halimi A, Hallin I, Hamsten C, Hansson M, Hedhammar M, Hercules G, Kampf C, et al.: A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005, 4:1920-1932.
• [24]Pontèn F, Jirström K, Uhlén M: The human protein atlas-a tool for pathology. J Pathol 2008, 216:387-393.
• [25]Sizemore SS, Cicek MM, Sizemore NN, Ng KPK, Casey GG: Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res 2007, 67:6183-6191.